1.
Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study
by Kuo, Chang-Fu
Annals of the rheumatic diseases, 2015, Vol.74 (4), p.661-667
2.
Paracetamol: not as safe as we thought? A systematic literature review of observational studies
by Roberts, Emmert Emmert
Annals of the rheumatic diseases, 2015, Vol.75 (3), p.552-559
3.
Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
by Bruce, Ian N
Annals of the rheumatic diseases, 2015, Vol.74 (9), p.1706-1713
4.
A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexat...
by Yoo, Dae Hyun
Annals of the rheumatic diseases, 2013, Vol.72 (10), p.1613-1620
5.
Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
by Keystone, E C
Annals of the rheumatic diseases, 2009, Vol.68 (6), p.789-796
6.
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with...
by Park, Won
Annals of the rheumatic diseases, 2013, Vol.72 (10), p.1605-1612
7.
Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)
by Dougados, Maxime
Annals of the rheumatic diseases, 2014, Vol.73 (1), p.62-68
8.
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
by Kavanaugh, Arthur
Annals of the rheumatic diseases, 2014, Vol.73 (6), p.1020-1026
9.
Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)
by Isenberg, David
Annals of the rheumatic diseases, 2015, Vol.74 (11), p.2006-2015
10.
Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study
by Coghlan, J Gerry
Annals of the rheumatic diseases, 2014, Vol.73 (7), p.1340-1349
11.
Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab
by Listing, Joachim
Annals of the rheumatic diseases, 2015, Vol.74 (2), p.415-421
12.
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-t...
by Ritchlin, Christopher
Annals of the rheumatic diseases, 2014, Vol.73 (6), p.990-999
13.
Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients
by van Vollenhoven, Ronald F
Annals of the rheumatic diseases, 2013, Vol.72 (9), p.1496-1502
14.
Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)
by Sieper, Joachim
Annals of the rheumatic diseases, 2013, Vol.72 (6), p.815-822
15.
Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial
by Burmester, Gerd-Rűdiger
Annals of the rheumatic diseases, 2015, Vol.74 (6), p.1037-1044
16.
A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy
by Emery, Paul Paul
Annals of the rheumatic diseases, 2015, Vol.76 (1), p.51-57
17.
Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial
by Brunner, Hermine I
Annals of the rheumatic diseases, 2015, Vol.74 (6), p.1110-1117
18.
Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)
by Mease, P J
Annals of the rheumatic diseases, 2014, Vol.73 (1), p.48-55
19.
Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiograp...
by Kavanaugh, Arthur
Annals of the rheumatic diseases, 2014, Vol.73 (6), p.1000-1006
20.
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Ph...
by Landewé, R
Annals of the rheumatic diseases, 2014, Vol.73 (1), p.39-47
